Role of Platelet Chemokines, PF-4 and CTAP-III, in Cancer Biology

Overview

Journal J Hematol Oncol

Publisher Biomed Central

Specialties Hematology
Oncology

Date 2013 Jun 27

PMID 23800319

Citations 28

Authors

Katerina Pilatova

Kristina Greplova

Regina Demlova

Beatrix Bencsikova

Giannoula Lakka Klement

Lenka Zdrazilova-Dubska

Affiliations

Soon will be listed here.

Abstract

With the recent addition of anti-angiogenic agents to cancer treatment, the angiogenesis regulators in platelets are gaining importance. Platelet factor 4 (PF-4/CXCL4) and Connective tissue activating peptide III (CTAP-III) are two platelet-associated chemokines that modulate tumor angiogenesis, inflammation within the tumor microenvironment, and in turn tumor growth. Here, we review the role of PF-4 and CTAP-III in the regulation of tumor angiogenesis; the results of clinical trial using recombinant PF-4 (rPF-4); and the use of PF-4 and CTAP-III as cancer biomarkers.

Citing Articles

Platelet factors ameliorate thoracic aortic aneurysm and dissection by inhibiting the FGF-FGFR cascade activation in aortic-endothelial cell.

Wang J, He C, Chen Y, Hu X, Xu H, Liu J iScience. 2024; 27(10):110953.

PMID: 39381736 PMC: 11460509. DOI: 10.1016/j.isci.2024.110953.

TEP RNA: a new frontier for early diagnosis of NSCLC.

Wang Y, Dong A, Jin M, Li S, Duan Y J Cancer Res Clin Oncol. 2024; 150(2):97.

PMID: 38372784 PMC: 10876732. DOI: 10.1007/s00432-024-05620-w.

Plasma-derived small extracellular vesicles unleash the angiogenic potential in head and neck cancer patients.

Tengler L, Schutz J, Tiedtke M, Jablonska J, Theodoraki M, Nitschke K Mol Med. 2023; 29(1):69.

PMID: 37226100 PMC: 10207688. DOI: 10.1186/s10020-023-00659-w.

NLRP7 Enhances Choriocarcinoma Cell Survival and Camouflage in an Inflammasome Independent Pathway.

Reynaud D, Alfaidy N, Collet C, Lemaitre N, Sergent F, Miege C Cells. 2023; 12(6).

PMID: 36980199 PMC: 10099745. DOI: 10.3390/cells12060857.

New perspectives on the induction and acceleration of immune-associated thrombosis by PF4 and VWF.

Liu Z, Sun M, Hua M, Zhang H, Mu G, Zhou S Front Immunol. 2023; 14:1098665.

PMID: 36926331 PMC: 10011124. DOI: 10.3389/fimmu.2023.1098665.

References

Slungaard A, Fernandez J, Griffin J, Key N, Long J, Piegors D . Platelet factor 4 enhances generation of activated protein C in vitro and in vivo. Blood. 2003; 102(1):146-51. DOI: 10.1182/blood-2002-11-3529. View

Tunnacliffe A, Majumdar S, Yan B, Poncz M . Genes for beta-thromboglobulin and platelet factor 4 are closely linked and form part of a cluster of related genes on chromosome 4. Blood. 1992; 79(11):2896-900. View

Lecomte-Raclet L, Alemany M, Amiral J, Quentin G, Vissac A, Caen J . New insights into the negative regulation of hematopoiesis by chemokine platelet factor 4 and related peptides. Blood. 1998; 91(8):2772-80. View

Lambert M, Rauova L, Bailey M, Sola-Visner M, Kowalska M, Poncz M . Platelet factor 4 is a negative autocrine in vivo regulator of megakaryopoiesis: clinical and therapeutic implications. Blood. 2007; 110(4):1153-60. PMC: 1976471. DOI: 10.1182/blood-2007-01-067116. View

Hristov M, Zernecke A, Bidzhekov K, Liehn E, Shagdarsuren E, Ludwig A . Importance of CXC chemokine receptor 2 in the homing of human peripheral blood endothelial progenitor cells to sites of arterial injury. Circ Res. 2007; 100(4):590-7. DOI: 10.1161/01.RES.0000259043.42571.68. View

Lozano R, Redondo-Horcajo M, Jimenez M, Zilberberg L, Cuevas P, Bikfalvi A . Solution structure and interaction with basic and acidic fibroblast growth factor of a 3-kDa human platelet factor-4 fragment with antiangiogenic activity. J Biol Chem. 2001; 276(38):35723-34. DOI: 10.1074/jbc.M101565200. View

Jouan V, Canron X, Alemany M, Caen J, Quentin G, Plouet J . Inhibition of in vitro angiogenesis by platelet factor-4-derived peptides and mechanism of action. Blood. 1999; 94(3):984-93. View

Perollet C, Han Z, Savona C, Caen J, Bikfalvi A . Platelet factor 4 modulates fibroblast growth factor 2 (FGF-2) activity and inhibits FGF-2 dimerization. Blood. 1998; 91(9):3289-99. View

Kolber D, Knisely T, Maione T . Inhibition of development of murine melanoma lung metastases by systemic administration of recombinant platelet factor 4. J Natl Cancer Inst. 1995; 87(4):304-9. DOI: 10.1093/jnci/87.4.304. View

10.

Cervi D, Yip T, Bhattacharya N, Podust V, Peterson J, Abou-Slaybi A . Platelet-associated PF-4 as a biomarker of early tumor growth. Blood. 2007; 111(3):1201-7. DOI: 10.1182/blood-2007-04-084798. View

11.

Pandya N, Dhalla N, Santani D . Angiogenesis--a new target for future therapy. Vascul Pharmacol. 2006; 44(5):265-74. DOI: 10.1016/j.vph.2006.01.005. View

12.

Lambert M, Xiao L, Nguyen Y, Kowalska M, Poncz M . The role of platelet factor 4 in radiation-induced thrombocytopenia. Int J Radiat Oncol Biol Phys. 2011; 80(5):1533-40. PMC: 3134787. DOI: 10.1016/j.ijrobp.2011.03.039. View

13.

Peterson J, Zurakowski D, Italiano Jr J, Michel L, Connors S, Oenick M . VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients. Angiogenesis. 2012; 15(2):265-73. DOI: 10.1007/s10456-012-9259-z. View

14.

Han Z, Sensebe L, Abgrall J, Briere J . Platelet factor 4 inhibits human megakaryocytopoiesis in vitro. Blood. 1990; 75(6):1234-9. View

15.

Brandt E, Petersen F, Ludwig A, Ehlert J, Bock L, Flad H . The beta-thromboglobulins and platelet factor 4: blood platelet-derived CXC chemokines with divergent roles in early neutrophil regulation. J Leukoc Biol. 2000; 67(4):471-8. DOI: 10.1002/jlb.67.4.471. View

16.

Gay L, Felding-Habermann B . Contribution of platelets to tumour metastasis. Nat Rev Cancer. 2011; 11(2):123-34. PMC: 6894505. DOI: 10.1038/nrc3004. View

17.

Deutsch V, Bitan M, Friedmann Y, Eldor A, Vlodavsky I . Megakaryocyte maturation is associated with expression of the CXC chemokine connective tissue-activating peptide CTAP III. Br J Haematol. 2001; 111(4):1180-9. DOI: 10.1046/j.1365-2141.2000.02476.x. View

18.

Struyf S, Salogni L, Burdick M, Vandercappellen J, Gouwy M, Noppen S . Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 (platelet factor-4 variant) are mediated by CXCR3. Blood. 2010; 117(2):480-8. PMC: 3031477. DOI: 10.1182/blood-2009-11-253591. View

19.

Fivenson D, Faria D, Nickoloff B, Poverini P, Kunkel S, Burdick M . Chemokine and inflammatory cytokine changes during chronic wound healing. Wound Repair Regen. 2006; 5(4):310-22. DOI: 10.1046/j.1524-475X.1997.50405.x. View

20.

Strieter R, Polverini P, Kunkel S, Arenberg D, Burdick M, Kasper J . The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem. 1995; 270(45):27348-57. DOI: 10.1074/jbc.270.45.27348. View